RKVTF (Rakovina Therapeutics) Debt-to-Asset : 0.26 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Rakovina Therapeutics Debt-to-Asset?

Rakovina Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Rakovina Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1.03 Mil. Rakovina Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $3.92 Mil. Rakovina Therapeutics's debt to asset for the quarter that ended in Sep. 2024 was 0.26.

Rakovina Therapeutics Debt-to-Asset Historical Data

The historical data trend for Rakovina Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Debt-to-Asset Chart

Rakovina Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

0.26

Rakovina Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial										0.23	0.26	0.29	0.22	0.26

Competitive Comparison of Rakovina Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Rakovina Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rakovina Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Rakovina Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rakovina Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0.994)	/	3.837
	=	0.26

Rakovina Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.031)	/	3.918
	=	0.26

Rakovina Therapeutics (OTCPK:RKVTF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rakovina Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (OTCPK:RKVTF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

7JO:Germany RKV:Canada

Address

595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC, CAN, V6B 0A5

Website

https://www.rakovinatherapeutics.com

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some of its products in the pipeline include kt-2000 AI, kt-3000 series. Rakovina gained exclusive use of the Deep Docking AI Platform, enabling it to significantly speed up identifying potential drugs for DNA damage response.